


INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) UAB-11703/22	Application Number 10/776,119
		Applicant(s) John D. Mountz	
		Filing Date February 10, 2004	Group Art Unit

EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
AW	Andreansky et al. "Evaluation of Genetically Engineered Herpes Simplex Viruses as Oncolytic Agents for Human Malignant Brain Tumors" Cancer Research 57, pp. 1502-1509 (April 15, 1997).		
	Muruve et al. "Adenovirus-Mediated Expression of Fas Ligand Induces Hepatic Apoptosis after Systemic Administration and Apoptosis of Ex Vivo-Infected Pancreatic Islet Allografts and Isografts" Human Gene Therapy 8, pp. 955-963 (May 20, 1997).		
	Rosenfeld et al. "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium" Cell, Vol. 68, pp. 143-155 (January 10, 1992).		
	Connelly et al. "In Vivo Gene Delivery and Expression of Physiological Levels of Functional Human Factor VIII in Mice" Human Gene Therapy 6, pp. 185-193 (February 1995).		
	Bellon et al. "Aerosol Administration of a Recombinant Adenovirus Expressing CFTR to Cystic Fibrosis Patients: A Phase I Clinical Trial" Human Gene Therapy 8, pp. 15-25 (January 1, 1997).		
	Connelly et al. "High-Level Tissue-Specific Expression of Functional Human Factor VIII in Mice" Human Gene Therapy 7, pp. 183-195 (January 20, 1996).		
	Peng et al. "Construction of Recombinant Adeno-Associated Virus Vector Containing the Rat Preproinsulin II Gene" Journal of Surgical Research 69, 193-198 (1997).		
	Wagner et al. "Toward Cystic Fibrosis Gene Therapy" Annu. Rev. Med. 48: 203-16 (1997).		
	Sata et al. "Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response" Proc. Natl. Acad. Sci. USA, Vol. 9, pp. 1213-1217 (February 1998).		
	Judge et al. "Functional analysis of a recombinant Fas ligand construct" Gastroenterology, Vol. 112, No. 4, p. A1007 (April 1997).		
	Miller et al. "Targeted vectors for gene therapy" FASEB J. 9: 190-199 (1995).		
	Verma et al. "Gene therapy-promises, problems and prospects" Nature Vol. 389: 239-242 (1997).		
			
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">EXAMINER</td> <td style="width: 50%;">DATE CONSIDERED</td> </tr> </table>		EXAMINER	DATE CONSIDERED
EXAMINER	DATE CONSIDERED		

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) UAB-11703/22	Application Number 10/776,119
		Applicant(s) John D. Mountz	
		Filing Date February 10, 2004	Group Art Unit
*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
AW	Miller et al. "Targeted vectors for gene therapy" FASEB J. 9: 190-199 (1995).		
	Verma et al. "Gene therapy-promises, problems and prospects" Nature Vol. 389: 239-242 (1997).		
	Marshall "Gene Therapy's Growning Pains" Science Vol. 269: 1050-1055 (1995).		
	Deonarain "Ligand-targeted receptor-mediated vectors for gene delivery" Exp. Opin. Ther. Patents 8(1); 53-69 (1998).		
	Orkins et al. "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy" (1995)		
EXAMINER /Anne Marie Wehbe/ (11/06/2006)		DATE CONSIDERED 11/06/2006	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.